MedTrace Logo

Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)

NCT07319910 · Status: TEMPORARILY_NOT_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-01-06

No results posted yet for this study

Summary

The EF-54 program (PANOVA-3CA) is a continued access program for adults with locally advanced pancreatic cancer to access TTFields therapy in combination with gemcitabine and nab-paclitaxel. The purpose of the program is to allow eligible patients to have access to TTFields while the NovoTTF-200T system is under FDA review. Safety and device performance will be monitored during routine clinical care.

Conditions

  • Locally Advanced Pancreatic Adenocarcinoma

Interventions

DEVICE

TTFields

TTFields is a non-invasive locoregional therapy that uses alternating electric fields. TTFields are delivered to the abdomen though adhesive transducer arrays connected to the NovoTTF-200T system.

DRUG

Gemcitabine

per standard of care

DRUG

Nab paclitaxel

per standard of care

Sponsors & Collaborators

  • NovoCure GmbH

    lead INDUSTRY

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07319910 on ClinicalTrials.gov